A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Opicinumab (Primary)
- Indications Multiple sclerosis; Optic neuritis
- Focus Adverse reactions
- Sponsors Biogen
- 07 Oct 2016 Status changed from active, no longer recruiting to completed.
- 05 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.